Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

This study has been completed.
American Diabetes Association
Information provided by (Responsible Party):
Guillermo Umpierrez, Emory University Identifier:
First received: September 12, 2008
Last updated: July 7, 2014
Last verified: July 2014
Obesity is common in African-American patients with newly diagnosed diabetes who present with diabetic ketoacidosis (DKA).1 Despite the presentation with severe symptoms of insulinopenia and ketoacidosis, clinical and immunogenetic observations indicate that most obese AA patients with DKA have type 2 diabetes. In such patients, our previous studies reveal: a) at presentation, obese AA patients with DKA have markedly de-creased pancreatic insulin secretion, lower than in obese non-DKA patients admitted with comparable hyperglycemia, but significantly greater than in lean patients with DKA;2 b) aggressive diabetic management results in significant improvement in b-cell function and insulin sensitivity sufficient to allow discontinuation of insulin therapy within 3 months of follow-up.2, 3 Based on these observations we conclude that similar to obese patients with hyperglycemia, most obese AA with DKA have type 2 diabetes, and that although defects in both insulin secretion and insulin action are present, transient b-cell failure is the primary defect in the development of ketoacidosis.

Condition Intervention
Drug: Intralipid 20%
Drug: Glucose infusion

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

Resource links provided by NLM:

Further study details as provided by Emory University:

Primary Outcome Measures:
  • First Phase Insulin Release (FPIR) [ Time Frame: at the end of 20 hours ]
    Calculated as the sum of the insulin levels at 2, 3, 4, and 5 min after infusion

Secondary Outcome Measures:
  • To Determine if Hyperglycemia-induced Reduced Insulin Secretion is the Result of Beta-cell Exhaustion or Beta-cell Desensitization. [ Time Frame: 4 years ]

Enrollment: 28
Study Start Date: March 2004
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Subjects with ketosis-prone diabetes
Obese African-Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA)
Drug: Intralipid 20%
48hr infusion with intralipid at 40ml/hr
Drug: Glucose infusion
Glucose infusion for 20 hours at 200 mg/m2/min
Active Comparator: Subjects with ketosis-resistant diabetes
Obese African-American with type 2 diabetes with hyperglycemia but without ketosis
Drug: Intralipid 20%
48hr infusion with intralipid at 40ml/hr
Drug: Glucose infusion
Glucose infusion for 20 hours at 200 mg/m2/min
Active Comparator: Control
Obese African-American nondiabetic subjects
Drug: Glucose infusion
Glucose infusion for 20 hours at 200 mg/m2/min

Detailed Description:
Obese AA patients with a history of DKA who later experience near-normoglycemia remission represent an ideal population in which to define the sequence of events that lead to b-cell dysfunction in type 2 diabetes. We hypothesize that obese AA with DKA will prove particularly susceptible to b-cells dysfunction due to sustained elevations of plasma glucose (glucose toxicity) and/or free fatty acid levels (lipotoxicity).

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Obese African American subjects (BMI equal or greater than 30)
  2. age 18-65,
  3. patients with a history of diabetic ketoacidosis as defined by the ADA criteria
  4. patients admitted with hyperglycemia but without ketoacidosis (BG greater than 400ml/dl without evidence of ketosis/ketones
  5. obese nondiabetic controls (BMI >30; ruled out for diabetes with a 75g oral glucose tolerance test)

Exclusion Criteria:

  1. patients with positive autoimmune markers [islet cell (ICA) or Glutamic acid decarboxylase (GAD) autoantibodies];
  2. patients with significant medical or surgical illness, including but not limited to myocardial ischemia, congestive heart failure, chronic renal insufficiency, liver failure, and infectious processes;
  3. patients with recognized or suspected endocrine disorders associated with increased insulin resistance, such as hypercortisolism, acromegaly, or hyperthyroidism;
  4. patients with bleeding disorders, thrombocytopenia, or abnormalities in coagulation studies;
  5. patients with fasting hyperglycemia (blood glucose > 120 mg/dl) after discontinuation of insulin therapy, and 6) pregnancy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00753142

United States, Georgia
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
Sponsors and Collaborators
Emory University
American Diabetes Association
Principal Investigator: Guillermo Umpierrez, MD Emory University
  More Information

Responsible Party: Guillermo Umpierrez, Professor, Emory University Identifier: NCT00753142     History of Changes
Other Study ID Numbers: 898-2003
Study First Received: September 12, 2008
Results First Received: July 7, 2014
Last Updated: July 7, 2014

Keywords provided by Emory University:

Additional relevant MeSH terms:
Glucose Metabolism Disorders
Metabolic Diseases
Soybean oil, phospholipid emulsion
Fat Emulsions, Intravenous
Parenteral Nutrition Solutions
Pharmaceutical Solutions processed this record on May 23, 2017